Rocky Mountain Uveitis Research
Rocky Mountain Uveitis is proud to be a regional center for clinical research trials in uveitis. Over the past 15 years, Dr. Dacey has served as a principal investigator for most of the major uveitis clinical trials.
These have included:
- Topical treatments, in the form of novel eyedrop therapies
- New medications injected into the vitreous to treat posterior segment inflammatory diseases
- Cutting edge systemic medications that are being evaluated for the prevention of uveitis flares
We have a long history of working closely with pharmaceutical companies. Dr. Dacey is passionate about actively working towards new potential breakthroughs in uveitis treatment. He has also served on many advisory boards, speaker bureaus, and physician data review boards, in addition to chairing the clinical research department at Colorado Retina Associates for many years. These roles have allowed him to be very experienced in all phases of drug development, from initial phase 1 studies through post-FDA approval marketing. As a result, RMU patients will be able to access every potential medication, from established therapies to the very latest in drug development.
We are excited to bring these options to our patients; please feel free to ask us about clinical trials at your next appointment!